Wang Tuo, Guo Zijian
State Key Laboratory of Coordination Chemistry, Nanjing University, Nanjing 210093, P.R. China.
Curr Med Chem. 2006;13(5):525-37. doi: 10.2174/092986706776055742.
As one of the most important essential transition metals, copper is involved in a variety of biological processes such as embryo development, connective tissue formation, temperature control and nerve cell function. It is also related to severe diseases such as Wilson's and Menkes diseases and some neurological disorders. Novel components of copper homeostasis include copper-transporting P-type ATPases, Menkes and Wilson proteins, and copper chaperones in humans have been identified and characterized at the molecular level. These findings have paved the way towards better understanding of the role of copper deficiency or copper toxicity in physiological and pathological conditions. Therefore, organic compounds that can interfere with copper homeostasis may find therapeutic application in copper-dependent diseases. The antitumor activity of copper complexes was reported several decades ago, and many new complexes have demonstrated great antitumor potential. Copper complexes may have relatively lower side effects than platinum-based drugs, and are suggested to be able to overcome inherited or acquired resistance of cisplatin. In this overview, the most recent advances in copper homeostasis, copper-related chelation therapy and design of copper-based antitumor complexes will be summarized.
作为最重要的必需过渡金属之一,铜参与多种生物过程,如胚胎发育、结缔组织形成、体温调节和神经细胞功能。它还与诸如威尔逊氏病和门克斯病等严重疾病以及一些神经紊乱有关。铜稳态的新成分包括铜转运P型ATP酶、门克斯蛋白和威尔逊蛋白,并且在分子水平上已经鉴定并表征了人类中的铜伴侣蛋白。这些发现为更好地理解铜缺乏或铜毒性在生理和病理条件下的作用铺平了道路。因此,能够干扰铜稳态的有机化合物可能在铜依赖性疾病中找到治疗应用。几十年前就报道了铜配合物的抗肿瘤活性,并且许多新的配合物已显示出巨大的抗肿瘤潜力。铜配合物可能比铂类药物具有相对较低的副作用,并且被认为能够克服顺铂的遗传性或获得性耐药性。在本综述中,将总结铜稳态、铜相关螯合疗法和铜基抗肿瘤配合物设计方面的最新进展。